Dr. Reddy's Labs launches Versavo in India to treat several types of cancers

Dr. Reddy's Laboratories Ltd. announced that it has launched Versavo (bevacizumab), a biosimilar of Roches Avastin in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer).

Dr. Reddy's Versavo is available in strengths of 100mg and 400mg single use vials.

MV Ramana, CEO - India and emerging markets, Dr. Reddy's Laboratories, said, We regard the good health of our patients as our responsibility and are committed to ensure that they always have access to the medicines they need. The launch of Versavo is another step in that journey and helps strengthen our oncology portfolio.

Dr. Raymond De Vr, global head, biologics, Dr. Reddy's Laboratories added Versavo will help improve access to high quality therapy at an affordable cost, addressing the needs of patients with different cancers in India.

Avastin and its biosimilars had India sales of approximately Rs. 223 crore MAT for the most recent twelve months ending in December 2018, according to Ipsos.

The company has six biosimilar products commercialized in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Merck announces positive event-free survival data from phase 3 KEYNOTE-522 study of Keytruda to treat triple-negative breast cancer